Medifast, Inc.

The stock is still in a downtrend regime, trading below both the 50-day and 200-day moving averages. It sits well under its 52-week high of $15.46, though above the $9.22 low, which points to a damaged but not broken base-building setup.

Wall Street is cautious: the consensus is Hold with a $12 target, modestly above the latest close. Recent target work has trended lower, with Stephens cutting its view to $12 from $15, reinforcing a neutral-to-wary stance rather than a fresh bullish call.

The earnings pattern is mixed but not collapsing: Medifast has beaten in 5 of the last 7 quarters, including a 63.5% EPS beat in the most recent reported quarter. The next print is expected to remain loss-making, with the estimate at -$0.68 EPS, so shareholders should watch whether margins and revenue stabilization continue.

The signal is mildly constructive. Discretionary buying showed up from director Scott Schlackman with two purchases totaling 5,000 shares, while the larger recent share grants look like compensation-related activity rather than conviction buying. No notable insider selling has appeared in recent quarters.

Profitability remains under pressure, but cash generation is still positive. Gross margin is 70.1%, while operating margin is -7.21% and net margin is -5.79%, showing a business that still converts product sales efficiently even as top-line and earnings trends weaken.

Medifast looks more like a turnaround name than a clean growth comp: it has a low beta of 0.675 and trades at a discounted valuation profile versus healthier consumer peers. The setup favors investors who want cash-rich downside support, not premium multiple expansion.